53 citations,
May 2019 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
38 citations,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.
38 citations,
June 2004 in “Human Reproduction” The document suggests that clinical trials for PCOS should focus on meaningful primary outcomes like live birth rates, rather than less reliable surrogate markers.
12 citations,
March 2013 in “Cancer Causes & Control” Early balding, especially frontal, increases prostate cancer risk; more research needed.
10 citations,
February 2019 in “The New England Journal of Medicine” Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.
6 citations,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
April 2024 in “Academic dermatology” Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.
January 2024 in “International Journal of Health Science” Scalp cooling and low-power light therapy show promise in reducing chemotherapy-induced hair loss but need more research.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
159 citations,
September 2001 in “European Journal of Cancer Care” Chemotherapy-induced hair loss significantly affects patients' well-being, and nurses are key in helping them cope, but more research is needed to find effective treatments.
88 citations,
August 2014 in “Journal of the American Academy of Dermatology” Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
53 citations,
June 1982 in “The BMJ” Cooling the scalp below 22°C before and during chemotherapy can help prevent hair loss.
24 citations,
March 2014 in “British Journal of Dermatology” Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.
15 citations,
May 1997 in “Annals of Internal Medicine” Tamoxifen caused hair loss in a 52-year-old woman.
9 citations,
April 2014 in “Medical Hypotheses” Higher DHT in male baldness may protect against prostate cancer.
7 citations,
May 2020 in “Annals of palliative medicine” New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
6 citations,
January 2020 in “International Journal of Biological Sciences” Septin4 helps kill colon cancer cells by working with the protein BAX.
4 citations,
June 2015 in “Journal of Genetics/Journal of genetics” Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.
3 citations,
March 2018 in “BMC Cancer” Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.
1 citations,
April 2019 in “Actas Dermo-Sifiliográficas” New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
126 citations,
April 2015 in “Clinical, cosmetic and investigational dermatology” Choosing the right patients, using proper techniques, and having thorough knowledge are key to preventing and managing dermal filler complications.
59 citations,
August 2018 in “The oncologist” Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
29 citations,
October 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
11 citations,
October 2019 in “Cancers” Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
9 citations,
April 2022 in “Journal of radiation research” Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.
1 citations,
June 2001 in “Annals of Internal Medicine” The conclusion is that maintaining blinding in clinical trials is crucial for reliable results.
March 2024 in “PLoS medicine” Physical activity, height, and smoking affect prostate cancer risk.
November 2022 in “CARDIOMETRY” A group has developed therapies that show promise for treating cancer and various other conditions.
June 2001 in “Annals of Internal Medicine” The conclusion suggests that the zinc lozenge study is valid despite imperfect blinding, as many participants could not correctly identify their lozenge type.
50 citations,
January 2016 in “The FEBS journal” RANK is a key target in breast cancer treatment due to its role in tumor growth and bone metastasis.